Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 2/20 | 0.98 |
| ▸ | BLM | P54132 | 2/20 | 0.98 |
| ▸ | ESR1 | P03372 | 6/20 | 0.75 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.75 |
| ▸ | INPPL1 | O15357 | 1/20 | 0.75 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.75 |
| ▸ | DRD1 | P21728 | 1/20 | 0.75 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.75 |
| ▸ | KDR | P35968 | 1/20 | 0.75 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.75 |
| ▸ | LMNA | P02545 | 5/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.72 |
| ▸ | ATM | Q13315 | 2/20 | 0.72 |
| ▸ | PGR | P06401 | 2/20 | 0.72 |
| ▸ | AR | P10275 | 2/20 | 0.72 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.72 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.72 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.72 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.72 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Estramustine SCHEMBL7621246 | 1.00 | RECQL (0.98) | RECQLBLMESR1ADORA3INPPL1 | |
| Estramustine SCHEMBL13753350 | 0.99 | RECQL (1.00) | RECQLBLMESR1ADORA3INPPL1 | |
| Estramustine SCHEMBL29374661 | 0.99 | RECQL (1.00) | RECQLBLMESR1ADORA3INPPL1 | |
| Estramustine SCHEMBL2348477 | 0.99 | RECQL (1.00) | RECQLBLMESR1ADORA3INPPL1 | |
| Estramustine SCHEMBL4252 | 0.99 | RECQL (1.00) | RECQLBLMESR1ADORA3INPPL1 | |
| Estramustine SCHEMBL29349776 | 0.99 | RECQL (1.00) | RECQLBLMESR1ADORA3INPPL1 | |
| Estramustine SCHEMBL8173336 | 0.99 | RECQL (1.00) | RECQLBLMESR1ADORA3INPPL1 | |
| Estramustine SCHEMBL7200287 | 0.99 | RECQL (1.00) | RECQLBLMESR1ADORA3INPPL1 | |
| Estramustine SCHEMBL6353316 | 0.99 | RECQL (1.00) | RECQLBLMESR1ADORA3INPPL1 | |
| Estramustine SCHEMBL14031683 | 0.99 | RECQL (1.00) | RECQLBLMESR1ADORA3INPPL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118215490-A | T cells with cell surface expression of adenosine deaminase and uses thereof | 小利兰·斯坦福大学董事会 | 2024-06-18 | — | — | CN | disclosed |
| CN-115916261-A | Engineered IL-12 and IL-23 polypeptides and uses thereof | 小利兰·斯坦福大学董事会 | 2023-04-04 | — | — | CN | disclosed |
| CN-109971003-B | Preparation method of silicon resin nanoparticle dispersion and silicon resin nanoparticle dispersion | 万华化学集团股份有限公司 | 2021-10-22 | — | — | CN | disclosed |
| US-10611761-B2 | Selective EP4 receptor antagonistic substance for treatment of cancer | ASKAT INC. (JP) | 2020-04-07 | — | — | US | disclosed |
| US-10555939-B2 | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione | CELGENE CORPORATION (US) | 2020-02-11 | — | — | US | disclosed |
| CN-110225908-A | Ethanesulfonic acid salt of quinoline derivative | 小野药品工业株式会社 | 2019-09-10 | — | — | CN | disclosed |
| EP-3067068-B1 | SODIUM META ARSENITE FOR USE IN THE TREATMENT OF MULTIPLE MYELOMA | KOMINOX INC (KY) | 2019-08-14 | — | — | EP | disclosed |
| CN-110114075-A | Disulfide-containing cell penetrating peptides and methods of making and using the same | 俄亥俄州国家创新基金会 | 2019-08-09 | — | — | CN | disclosed |
| CN-109971003-A | A kind of preparation method and silicone resin nanoparticle dispersion of silicone resin nanoparticle dispersion | 万华化学集团股份有限公司 | 2019-07-05 | — | — | CN | disclosed |
| CN-109867647-A | Carbonyl naphtho- [2,3-b] furan derivatives or its pharmaceutically acceptable salt that 3- replaces | 北京强新生物科技有限公司 | 2019-06-11 | — | — | CN | disclosed |
| WO-2007064045-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-06-07 | — | — | WO | disclosed |
| WO-2006121280-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING OF ARSENOUS ACID, ITS SODIUM SALT AND ITS DERIVATIVES INTENDED FOR THE TREATMENT OF UROGENITAL CANCER AND ITS METASTASIS | KOMIPHARM INTERNATIONAL CO., LTD. (KR) | 2006-11-16 | — | — | WO | disclosed |
| EP-1721615-A1 | Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis | Komipharm International Co., Ltd. (KR) | 2006-11-15 | — | — | EP | disclosed |
| CN-1832743-A | dosage form comprising AG013736 | AGOURON PHARMA (US) | 2006-09-13 | — | — | CN | disclosed |
| US-20050249770-A1 | Compositions and methods for treating or preventing inflammatory diseases | ANGIOTECH INTERNATIONAL AG (CH) | 2005-11-10 | — | — | US | disclosed |
| EP-1092433-B1 | USE OF ANTI.MICROTUBULE AGENTS FOR TREATING INFLAMMATORY RESPIRATORY DISEASES OF THE RESPIRATORY TRACT | ANGIOTECH INTERNAT GMBH (CH) | 2003-08-06 | — | — | EP | disclosed |
| US-6515016-B2 | Treating or preventing multiple sclerosis, by administering an antimicrotubule agent; treating various other inflammatory diseases | ANGIOTECH PHARMACEUTICALS, INC. (CA) | 2003-02-04 | — | — | US | disclosed |
| WO-1999062510-A2 | COMPOSITIONS COMPRISING ANTI-MICROTUBULE AGENTS FOR TREATING OR PREVENTING INFLAMMATORY DISEASES | ANGIOTECH PHARMACEUTICALS, INC. (CA) | 1999-12-09 | — | — | WO | disclosed |
| EP-0941089-A2 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING INFLAMMATORY DISEASES | Angiotech Pharmaceuticals, Inc. (CA) | 1999-09-15 | — | — | EP | disclosed |
| WO-1998024427-A2 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING INFLAMMATORY DISEASES | ANGIOTECH PHARMACEUTICALS, INC. (CA) | 1998-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10611761-B2 | Selective EP4 receptor antagonistic substance for treatment of cancer | PTGER4, PTGER1, PTGER2 | RECQL 4537/4885BLM 4754/4885ESR1 265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.